Drug-combination nanoparticles (DcNPs) administered subcutaneously represent a potential long-acting lymphatic-targeting treatment for HIV infection. The DcNP containing lopinavir (LPV)-ritonavir (RTV)-tenofovir (TFV), Targeted-Long-Acting-Antiretroviral-Therapy product candidate 101 (TLC-ART 101), has shown to provide long-acting lymphocyte-targeting performance in nonhuman primates. To extend the TLC-ART platform, we replaced TLC-ART 101 LPV with second-generation protease inhibitor, atazanavir (ATV). Pharmacokinetics of the ATV-RTV-TFV DcNP was assessed in macaques, in comparison to the equivalent free drug formulation and to the TLC-ART 101. After single subcutaneous administration of the DcNP formulation, ATV, RTV, and TFV concentrations were sustained in plasma for up to 14 days, and in peripheral blood mononuclear cells for 8 to 14 days, compared with 1 to 2 days in those macaques treated with free drug combination. By 1 week, lymph node mononuclear cells showed significant levels for all 3 drugs from DcNPs, whereas the free controls were undetectable. Compared with TLC-ART 101, the ATV-RTV-TFV DcNP exhibited similar lymphocyte-targeted long-acting features for all 3 drugs and similar pharmacokinetics for RTV and TFV, whereas some pharmacokinetic differences were observed for ATV versus LPV. The present study demonstrated the flexibility of the TLC-ART's DcNP platform to include different antiretroviral combinations that produce targeted long-acting effects on both plasma and cells.
This study suggests that the interplay between maternal flow and villous structure affects the efficiency of placental transfer but predicted that flow rate will be the major determinant of transfer.
Over 50 million people have been infected with the SARS-CoV-2 virus, while around 1 million have died due to COVID-19 disease progression. COVID-19 presents flu-like symptoms that can escalate, in about 7 e10 days from onset, into a cytokine storm causing respiratory failure and death. Although social distancing reduces transmissibility, COVID-19 vaccines and therapeutics are essential to regain socioeconomic normalcy. Even if effective and safe vaccines are found, pharmacological interventions are still needed to limit disease severity and mortality. Integrating current knowledge and drug candidates (approved drugs for repositioning among >35 candidates) undergoing clinical studies (>3000 registered in ClinicalTrials.gov), we employed Systems Pharmacology approaches to project how antivirals and immunoregulatory agents could be optimally evaluated for use. Antivirals are likely to be effective only at the early stage of infection, soon after exposure and before hospitalization, while immunomodulatory agents should be effective in the later-stage cytokine storm. As current antiviral candidates are administered in hospitals over 5e7 days, a long-acting combination that targets multiple SARS-CoV-2 lifecycle steps may provide a long-lasting, single-dose treatment in outpatient settings. Long-acting therapeutics may still be needed even when vaccines become available as vaccines are likely to be approved based on a 50% efficacy target.
Key points
Placental structure and function can be modified as a result of maternal obesity affecting materno‐fetal fatty acids (FA) transport.
We report for the first time, in humans and in vivo, the kinetics of placental FA transfer in normo‐weight and in normolipemic obese pregnant women using stable isotopes.
The administration of different tracer FA with similar behaviour to the mother at different time points allows the collection of kinetic information on materno‐fetal transfer of FA despite only one sample of placenta and cord can be collected per subject.
Computational modelling showed a good fit to the data when considering all maternal plasma lipid classes but not when based only on non‐esterified FA.
The novel approach using multiple tracer FA administration combined with computational modelling shows a consistent time course of placental tracer FA and predicted total FA accumulation.
Abstract
We analyse for the first time the in vivo materno‐fetal kinetic transfer of fatty acids (FA) labelled with stable isotopes in control and obese (OB) pregnant women. Labelled FA with a similar metabolism (stearic acid: 13C‐SA; palmitic acid: 13C‐PA; oleic acid: 13C‐OA) were orally administered at −4 h, −8 h and −12 h, respectively prior to elective caesarean section to 10 pregnant women with a body mass index >30 (OB) and 10 with a body mass index in the range 20–25 (NW). Placenta, venous and arterial cord blood were collected obtaining a wide range of FA enrichments. A combined experimental and computational modelling analysis was applied. FA fractional synthesis rate (FSR) in placenta was 11–12% h–1. No differences were observed between NW and normo‐lipidemic OB. It was not possible to estimate FA FSR in cord blood with this oral bolus dose approach. Computational modelling demonstrated a good fit to the data when all maternal plasma lipid classes were included but not with modelling based only on the non‐esterified FA fraction. The estimated materno‐fetal 13C‐FA transfer was ∼1%. In conclusion, our approach using multiple 13C‐FA tracers allowed us to estimated FSR in placental/maternal plasma but not in fetal/maternal compartments. Computational modelling showed a consistent time course of placental 13C‐FA transfer and predicted total fetal FA accumulation during the experiment. We conclude that, in addition to non‐esterified FA fraction in the maternal circulation, maternal plasma very low‐density lipoprotein and other lipoproteins are important contributors to placental FA transfer to the fetus.
Membrane transporters are considered essential for placental amino acid transfer,
but the contribution of other factors, such as blood flow and metabolism, is
poorly defined. In this study we combine experimental and modeling approaches to
understand the determinants of [14C]phenylalanine transfer across the
isolated perfused human placenta. Transfer of [14C]phenylalanine
across the isolated perfused human placenta was determined at different maternal
and fetal flow rates. Maternal flow rate was set at 10, 14, and 18 ml/min for 1
h each. At each maternal flow rate, fetal flow rates were set at 3, 6, and 9
ml/min for 20 min each. Appearance of [14C]phenylalanine was measured
in the maternal and fetal venous exudates. Computational modeling of
phenylalanine transfer was undertaken to allow comparison of the experimental
data with predicted phenylalanine uptake and transfer under different initial
assumptions. Placental uptake (mol/min) of [14C]phenylalanine
increased with maternal, but not fetal, flow. Delivery (mol/min) of
[14C]phenylalanine to the fetal circulation was not associated
with fetal or maternal flow. The absence of a relationship between placental
phenylalanine uptake and net flux of phenylalanine to the fetal circulation
suggests that factors other than flow or transporter-mediated uptake are
important determinants of phenylalanine transfer. These observations could be
explained by tight regulation of free amino acid levels within the placenta or
properties of the facilitated transporters mediating phenylalanine transport. We
suggest that amino acid metabolism, primarily incorporation into protein, is
controlling free amino acid levels and, thus, placental transfer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.